One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P.MitraaVikram M.Narayana†SharadaMokkapatiaTannerMiestaStephen A.BoorjianbMehrdadAlemozaffarcBadrinath R.KonetydNeal D.ShoreeLeonard G.GomellafAshish M.KamataTrinity J.BivalacquagJeffrey S.MontgomeryhSeth P.LerneriJ. ErikBusbyjMichaelPochkPaul L.CrispenlGary D.SteinbergmAnne K.Schuckmann…Colin P.N.Dinneya
Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex–associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome
SounakGuptaaChristine M.LohsebRossRowseyaMichael R.McCarthyaWeiShenaLorenHerrera-HernandezaStephen A.BoorjiancR.Houston ThompsoncRafael E.JimenezaBradley C.LeibovichcJohn C.Chevillea
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
GiuliaBaciarelloaRemyDelvabGwenaelleGraviscYoussefTazidPhilippeBeuzeboceMarineGross-GoupilfEmmanuelleBompasgFlorenceJolyhCharlotteGreilsameriThierry Nguyen TanHonjPhilippeBarthelemykStephaneCulinelJean FrancoisBerdahmMathildeDeblocknRaffaeleRattaeAudeFlechonoCarolineCheneaupAlineMaillardq…KarimFizazia
Patient Preference or Indifference: Learning from the CABADOC Study
Anthony M.JoshuaabcHowardGurneydefHaryana M.DhillonghMeganCrumbakerabc
Inherited TP53 Variants and Risk of Prostate Cancer
Kara N.Maxwellabx†Heather H.Chengcd†JacquelynPowersa†RomanGulatidElisa M.LedeteCaseyMorrisonfAnhLeaRyanHauslerayJillStopfergSophieHymangWendyKohlmannhAnneNaumerhJennieVagherhSamantha E.GreenberghLorraineNayloriMercyLaurinoiEric Q.KonnickjBrian H.Shirtsju…Colin C.Pritchardju‡
TP53: Another Piece of the Prostate Cancer Genetics Puzzle
ElenaCastroab
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Edmond M.KwanabLaviniaSpaincdeAngelynAntondefChun L.GanbLindaGarrettbDeborahChangbElizabethLiowbCaitlinBennetteTiantianZhenggJianjunYugChaoDaigPanDugShidongJiagHeidiFettkehiClaireAbou-SeifjGargiKotharikMarkShawikPhillipParentede…Arun A.Azadaci
Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer
UmangSwamiNicolasSayeghNeerajAgarwal
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
LaurenceAlbigesaNizar M.TannirbMauricioBurottocDavidMcDermottdElizabeth R.PlimackePhilippeBarthélémyfCamilloPortag1ThomasPowleshFredeDonskoviSabyGeorgejChristian K.KollmannsbergerkHowardGurneylMarc-OliverGrimmmYoshihikoTomitanDanielCastellanooBrian I.RinipToni K.ChoueiriqDavidLeungr…Robert J.Motzeru
“Immune-Cell Pawns� Plot Promotion and Corner Kidney Cancer: CheckMate 214
FurkanDursunabChethanRamamurthybcDharamKaushikab
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
CristinaMasiniaCinziaIottibUgoDe GiorgicRoberto SalvatoreBelliadSebastianoButieFrancescoSalarolifIlariaZampivagRenzoMazzarottohClaudiaMucciariniiMaria GiuseppaVitalejAlessioBrunikFrankLohrkGiuseppeProcopiolOrazioCaffomFrancoNolenFrancoMorellioSusanneBaierpConsueloButtiglieroq…CarminePintoa
Solving the Stereotactic Body Radiotherapy and Checkpoint Inhibitor Puzzle in Metastatic Renal Cell Carcinoma
Sophia C.KamranaXinGaob
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
KarinWeléna1EbbaRosendalbc1MagnusGissléndeAnnasaraLenmanbEvaFreyhultfOsvaldoFonseca-RodrÃguezgDanielBremelldJohanStranneaÃ…se ÖstholmBalkhedhKatarinaNiwardhJohannaRepogDavidRobinssoniAnna J.HenningssonhjJohanStyrkekMartinAngelingElisabethLindquistgAnnikaAllardbMiriamBeckerb…AndreasJosefssonako2
Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort
Matthew B.ClementsaThomas M.AtkinsonbGuido M.DalbagniaYuelinLibAndrew J.VickerscHarry W.HerraS. MacheleDonataJaspreet S.SandhuaDaniel S.SjobergcAmy L.TincBruce D.RapkindBernard H.Bochnera
Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition
MarcSbizzeraabNicolasMorel-JournelabAlainRuffionabSébastienCrouzetacPhilippePaparelabDamienCarnicelliabPaulNeuvilleab
Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
KatherineFleshneraSigrid V.Carlssonbcd
Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer
WoutDevliesGaëtanDevosHenriDecloedtBramVansevenantFrankClaessensStevenJoniau
Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate
HalukÖzenaLeventTürkerib
Re: Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort
MarkusHohenfellnerRuthHimmelsbach
Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
Patrick J.HensleyAshish M.Kamat
Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma
Diana E.MageeAlexanderKutikov
Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145–8
ZhanWangYangZhaoYushiZhang
Re: Marc Sbizzera, Nicolas Morel-Journal, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. 2022;81:305–12
JasSingh
Reply to Jas Singh’s Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. 2022;81:305–12
MarcSbizzeraabNicolasMorel-JournelabDamienCarnicelliabAlainRuffionabPhilippePaparelabSébastienCrouzetacPaulNeuvilleab
Re: Luke Harper, T. Blanc, M. Peycelon, et al. Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. Eur Urol. 2022;81:64–72
Abhay SinghGaurPrasantNayak
Reply to Abhay Singh and Prasant Nayak’s Letter to the Editor re: Luke Harper, T. Blanc, M. Peycelon, et al. Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. Eur Urol. 2022;81:64–72
LukeHarper
Re: Luke Harper, T. Blanc, M. Peycelon, et al. Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. Eur Urol. 2022;81:64–72
DeepanshDalelaKristinaSuson
Reply to Deepansh Dalela and Kristina Suson’s Letter to the Editor re: Luke Harper, T. Blanc, M. Peycelon, et al. Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. Eur Urol. 2022;81:64–72
LukeHarper
